Summary: A study evaluating the efficacy of Lenacapavir (LEN) and Emitricitabine
(F/TDF)/Tenofovir Alafenamide (F/TAF) in preventing HIV infection among
adolescent girls and young women (AGYW)
Study Sponsor: Gilead Sciences, Inc
Study Principle Investigator: Dr. Godfrey Kigozi
Study Site: AMBSO -Masaka Research Site
Update: Currently at Open Label Extension Phase (OLE)
Interim Results:
Out of the 5338 HIV negative cisgender females 16-25 years recruited, 55HIV incident cases (0 Len/2134 participants. 39 F/TAF/2136, 16F/TDF/1068.